News & Articles

Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19

Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19 Press Release Covid-19 project 12 May 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-...
Read More

Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8 and CD4 T Cells

Zhang et al – 2009 (view in PDF)...
Read More

Mouse Model for Pre-Clinical Study of Human Cancer Immunotherapy

Ya Z. et al – 2015 (view in PDF)...
Read More

WHO guidelines on nonclincial evaluation of vaccines

WHO Guideline – nonclinical_evaluation_vaccines_nov_2003...
Read More

A Bayesian design for phase I cancer therapeutic vaccine trials

Wang, Rosner and Roden – 2019 (view in PDF)...
Read More

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

van Poelgeest e al – 2013 (view in PDF)...
Read More

ELISpot for measuring human immune responses to vaccines

Slota et al – 2011 (view in PDF)...
Read More

Vaccine Immunology

Siegrist C-A – 2012...
Read More

Phase I Trial of Overlapping Long Peptides from a Tumor Self- Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Sabbatini et al -2012 (view in PDF)...
Read More

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation

Rosalia et al – 2013 (view in PDF)...
Read More
en_GBEnglish